Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

Abstract : We characterized the mechanism of action of the neuregulin-non-competitive anti-HER3 therapeutic antibody 9F7-F11 that blocks the PI3K/AKT pathway, leading to cell cycle arrest and apoptosis in vitro and regression of pancreatic and breast cancer in vivo. We found that 9F7-F11 induces rapid HER3 down-regulation. Specifically, 9F7-F11-induced HER3 ubiquitination and degradation in pancreatic, breast and prostate cancer cell lines was driven mainly by the itchy E3 ubiquitin ligase (ITCH/AIP4). Overexpression of the ITCH/AIP4 inhibitor N4BP1 or small-interfering RNA-mediated knockdown of ITCH/AIP4 inhibited HER3 ubiquitination/degradation and PI3K/AKT signaling blockade induced by 9F7-F11. Moreover, 9F7-F11-mediated JNK1/2 phosphorylation led to ITCH/AIP4 activation and recruitment to HER3 for receptor ubiquitination and degradation. ITCH/AIP4 activity was activated by the deubiquitinases USP8 and USP9X, as demonstrated by RNA interference. Taken together, our results suggest that 9F7-F11-induced HER3 ubiquitination and degradation in cancer cells mainly occurs through JNK1/2-dependent ITCH/AIP4 activation.
Liste complète des métadonnées

Littérature citée [66 références]  Voir  Masquer  Télécharger

https://hal.umontpellier.fr/hal-02297403
Contributeur : Anthony Herrada <>
Soumis le : jeudi 26 septembre 2019 - 10:29:52
Dernière modification le : vendredi 27 septembre 2019 - 16:21:19
Document(s) archivé(s) le : dimanche 9 février 2020 - 22:50:17

Fichier

9455-143964-3-PB.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Citation

Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, Christel Larbouret, Marie-Alix Poul, et al.. The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. Oncotarget, Impact journals, 2016, 7 (24), pp.37013-37029. ⟨10.18632/oncotarget.9455⟩. ⟨hal-02297403⟩

Partager

Métriques

Consultations de la notice

42

Téléchargements de fichiers

76